These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3680560)

  • 1. Effect of a sustained-release formulation of trimazosin in mild to moderate hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    J Clin Pharmacol; 1987 Feb; 27(2):101-5. PubMed ID: 3680560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimazosin for the treatment of hypertensive patients failing to respond to thiazides.
    Oberman A; Pool PE
    Am Heart J; 1983 Nov; 106(5 Pt 2):1258-64. PubMed ID: 6356855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term haemodynamic effects of sustained-release trimazosin at rest and during exercise in essential hypertension.
    Omvik P; Lund-Johansen P
    Eur J Clin Pharmacol; 1991; 40(2):131-4. PubMed ID: 2065694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension.
    Webb DJ; Hutcheson MJ; Robertson MP; Murray GD; Lorimer AR; Robertson JI
    Scott Med J; 1985 Apr; 30(2):106-10. PubMed ID: 3892676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of trimazosin: an effective and safe antihypertensive agent.
    Taylor CR; Leader JP; Singleton W; Munster EW; Falkner FC; O'Neil JA
    Am Heart J; 1983 Nov; 106(5 Pt 2):1269-81. PubMed ID: 6227228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin.
    Weber MA; Brewer DD; Drayer JI; Aronow WS; Lipson JL; Ricci BA
    Clin Pharmacol Ther; 1982 May; 31(5):572-8. PubMed ID: 7042174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of trimazosin and propranolol in essential hypertension.
    Helgeland A
    Am Heart J; 1983 Nov; 106(5 Pt 2):1253-8. PubMed ID: 6356854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha 1-adrenergic receptor antagonist, trimazosin, in hypertension.
    Sampieri L; Cuspidi C; Boselli L; Angioni L; Castiglioni G; Zanchetti A; Mancia G
    Cardiovasc Drugs Ther; 1988 Jan; 1(5):535-42. PubMed ID: 2908716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind study of trimazosin and methyldopa in hypertensive patients receiving polythiazide.
    Moyer RR
    Am Heart J; 1983 Nov; 106(5 Pt 2):1250-3. PubMed ID: 6356853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical hemodynamic profile of trimazosin in hypertension.
    Pool PE; Seagren SC; Salel AF
    Am Heart J; 1983 Nov; 106(5 Pt 2):1237-42. PubMed ID: 6356851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of trimazosin and methyldopa in hypertension.
    Aronow WS; Tobis J; Hughes D; Siegel J; Easthope J
    Clin Pharmacol Ther; 1977 Oct; 22(4):425-9. PubMed ID: 332438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomic, systemic, and renal hemodynamic actions of trimazosin in hypertensive patients.
    Chrysant SG
    Am Heart J; 1983 Nov; 106(5 Pt 2):1243-50. PubMed ID: 6356852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive efficacy of optimally titrated doses of once-daily sustained-release diltiazem: a placebo-controlled trial. DILPLACOMP Study Group.
    Ollivier JP; Wajman A; Stalla-Bourdillon A
    Cardiology; 1995; 86(6):481-7. PubMed ID: 7585759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes.
    Kuo SW; Pei-Dee ; Hung YJ; Hsieh AT; Wu LY; Hsieh CH; He CT; Yang TC; Lian WC
    Am J Hypertens; 2003 Aug; 16(8):623-8. PubMed ID: 12878366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension.
    Frishman WH; Zawada ET; Smith LK; Sowers J; Swartz SL; Kirkendall W; Lunn J; McCarron D; Moser M; Schnaper H
    Am J Cardiol; 1987 Mar; 59(6):615-23. PubMed ID: 3548301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
    Os I; Stokke HP
    J Cardiovasc Pharmacol; 1999 May; 33(5):791-7. PubMed ID: 10226868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group.
    Ambrosioni E; Safar M; Degaute JP; Malin PL; MacMahon M; Pujol DR; de Cordoüe A; Guez D
    J Hypertens; 1998 Nov; 16(11):1677-84. PubMed ID: 9856369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of trimazosin on serum lipid profiles in hypertensive patients.
    Singleton W; Taylor CR
    Am Heart J; 1983 Nov; 106(5 Pt 2):1265-8. PubMed ID: 6356856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.
    Tuteja R; Swarup D; Saxena GN; Bhandari S; Sharma P
    J Assoc Physicians India; 1999 Oct; 47(10):962-5. PubMed ID: 10778687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac muscle mass during vasodilation therapy of hypertension.
    Drayer JI; Gardin JM; Weber MA; Aronow WS
    Clin Pharmacol Ther; 1983 Jun; 33(6):727-32. PubMed ID: 6221856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.